Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

Capricor, which was seeking approval of Deramiocel for the treatment of cardiomyopathy associated with DMD, said the FDA issued a so-called complete response letter, indicating the agency won't ...

Capricor Therapeutics (NASDAQ:CAPR) shares fell Friday after the company announced it received a complete response letter from the U.S. Food and Drug Administration for its Biologics License ...

Prescription opioid abuse and its downstream effects have reached epidemic proportions in the United States. On May 26, the Food and Drug Administration (FDA) moved a step closer to providing help to ...

But collagen isn’t always kind. It’s an ephemeral visitor that begins to bid farewell as early as our 20s. If you’ve started ...

Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ...

If you’re looking for a way to improve your health, get motivated to exercise more, or another way to manage health condition ...

Mitolyn is a natural weight loss supplement designed to target a hidden cause of stubborn fat—poor mitochondrial health. Based on Harvard research ...

Most fitness experts and personal trainers will tell you that all you need are the basics, like protein powder and creatine, which are research-backed to help improve your performance. For anything ...

Milestone® Pharmaceuticals Inc. ('Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the 'Offering”) of its common shares, accompanying Series A warrants ...

New development at the University of Sheffield will double the research capacity of the world-leading research facility, ...

The U.S. Food and Drug Administration has published more than 200 complete response letters, or decision letters, sent as ...